Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
Breast Cancer, Non-metastatic
For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?
Related Questions
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Would you offer systemic therapy (TH) to a patient with HER2+ (3+), HR- high grade microinvasive breast cancer with single focus or multifocal?
What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?
How would you treat a patient with T1c HR-, HER2+ breast cancer, stage IV, with involvement of multiple bilateral axillary nodes and no evidence of distant metastasis?
In a premenopausal, receptor positive node positive woman with breast cancer who has regular menses prior to initiation of chemotherapy and then stops during chemotherapy, how do you determine the timing of ovarian suppression or treatment with medication or oophorectomy?
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
Does HER2 status or response to neoadjuvant therapy influence your decision to use ovarian function suppression in premenopausal patients with ER+ HER2+ tumors?